Ep-PAINE-nym



Grave’s Disease

 

Other Known AliasesAutoimmune hyperthyroidism

Definition – Hyperthyrodism caused by antibodies that stimulate T3/T4 secretion.  The most common antibodies are thyroid-secreting hormone (TSH) and thyrotropin receptor antibody (TRAb). 

Clinical SignificanceClassic clinical manifestations of hyperthyroidism include thyromegaly, ophthalmaopathy, resting tremor, palpitations, weight loss, heat intolerance.  For more in depth analysis of hyperthyroidism, see my 2017 talk at ASPA here.

History – Named after Robert James Graves (1796-1853), who was an prolific Irish physician, surgeon, and educator.  He was named Regius professor of the Institute of Medicine in Trinity College, founded the Dublin Journal of Medical and Chemical Sciences, and was a an early adopter of clinical bedside rounding and teaching with medical students. Dr. Graves wrote a routine clinical lecture series in the London Medical and Surgical Journal and first described a young female patient with ophthalmopathy and goiter in 1835.  Dr. Armand Trousseau then published the collection of these articles in 1864 entitled “Clinical Lectures on the Practice of Medicine” and gave him this eponym.  Another contribution of Dr. Graves was the creation of the second hand on watches to time pulses and the practice of providing food and water with patients with a fever, instead of the common practice of withholding nourishment.

Image result for robert james graves

 


References

  1. Firkin BG and Whitwirth JA.  Dictionary of Medical Eponyms. 2nd ed.  New York, NY; Parthenon Publishing Group. 1996.
  2. Bartolucci S, Forbis P.  Stedman’s Medical Eponyms.  2nd ed.  Baltimore, MD; LWW.  2005.
  3. Yee AJ, Pfiffner P. (2012).  Medical Eponyms (Version 1.4.2) [Mobile Application Software].  Retrieved http://itunes.apple.com.
  4. Whonamedit – dictionary of medical eponyms. http://www.whonamedit.com
  5. Graves RJ.  Newly Observed Affection of the Thyroid Gland. London Medical and Surgical Journal.  1835. Vol.7. Part 2. 512
  6. Graves RJ, Trousseau A.  Clinical Lectures on the Practice of Medicine.  1864.  Dublin.
  7. Smith TJ, Hegedüs L. Graves’ Disease. The New England journal of medicine. 2016; 375(16):1552-1565. [pubmed]

PAINE #PANCE Pearl – Endocrine



  1. What the two main sub-types of diabetes insipidus and how do you differentiate between the two?
  2. What are the two lesser known sub-types?


Answer

 

  1. The two main types of diabetes insipidus (DI) are central and nephrogenic.  The hallmark of DI is deficiency of vasopressin and you can think of central DI as an ABSOLUTE deficiency and nephrogenic as a RELATIVE deficiency.  Meaning, in central DI there is a problem with secretion of vasopressin from the posterior pituitary.  The kidneys are fine, there just isn’t any vasopressin to make the kidneys hold onto water.  In nephrogenic DI, there is plenty of circulating vasopressin (due to feedback to a normally functioning pituitary), but the kidneys are not responding to this stimulus.  Central DI is most commonly caused by head trauma, post-neurosurgery, or autoimmune issues.  Nephrogenic DI is most commonly caused by genetic defects in children, or renal problems in adults.  A simple test to differentiate between central and nephrogenic DI is a desmopressin challenge.  You can give desmopressin IN or SQ and measure urine osmolarity and volume every 30 minutes for 2 hours.  In central DI, you should see a decrease in urine volume and increase in urine osmolarity.  In nephogenic DI, nothing will change.
  2. There are 2 other sub-types of DI that you need to be aware of as well.  Gestational DI, which is considered a form of nephrogenic DI, can occur in the second/third trimester of pregnancy.  This manifests as a transient ADH resistance due to increased vasopressinase from the placenta.  The other subtype of DI is dipsogenic DI, which is a result of either a defect in the thirst center of the hypothalamus, or due to mental illness, which causes near constant polydipsia and polyuria.  This basically overpowers the circulating ADH

 


References

  1. Robertson GL. Diabetes insipidus: Differential diagnosis and management. Best practice & research. Clinical endocrinology & metabolism. 2016; 30(2):205-18. [pubmed]
  2. Aleksandrov N, Audibert F, Bedard MJ, Mahone M, Goffinet F, Kadoch IJ. Gestational diabetes insipidus: a review of an underdiagnosed condition. Journal of Obstetrics and Gynaecology Canada. 2010; 32(3):225-31. [pubmed]
  3. Perkins RM, Yuan CM, Welch PG. Dipsogenic diabetes insipidus: report of a novel treatment strategy and literature review. Clinical and experimental nephrology. 2006; 10(1):63-7. [pubmed]

Ep-PAINE-nym



Addison’s Disease

 

Other Known Aliasesprimary adrenal insufficiency

Definitionautoimmune destruction of the adrenal cortex that produces cortisol

Clinical SignificanceIn times of physiologic stress, the adrenal glands are unable to produce and secrete cortisol, which is a key hormone in the “fight-or-flight” response.  If the stress is significant (trauma, surgery, hemorrhage, etc.), then the patient can not mount a compensatory response to this stress and can have life-threatening consequences

History – Named after Thomas Addison (1795-1860), an English physician, who first wrote about the condition in a short note in the London Medical Gazette called “Anaemia – Disease of the Suprarenal Capsules”.  This was then followed up by the more well known article “On the Constitutional and Local Effects of Disease of the Suprarenal Capsule” in 1855, which is largely considered the beginning of the study of the adrenal glands.  The disease eponym was original given to Dr. Addison by the French physician, Armand Trousseau, after fierce debate among experts as to whether the disease actually existed.

Image result for thomas addison

Image result for on the constitution and local effects of disease of the suprarenal capsules

https://library.sydney.edu.au/collections/rare-books/online-exhibitions/medicine/AddisonConstitutional1855plate8.jpg


References

  1. Firkin BG and Whitwirth JA.  Dictionary of Medical Eponyms. 2nd ed.  New York, NY; Parthenon Publishing Group. 1996.
  2. Bartolucci S, Forbis P.  Stedman’s Medical Eponyms.  2nd ed.  Baltimore, MD; LWW.  2005.
  3. Yee AJ, Pfiffner P. (2012).  Medical Eponyms (Version 1.4.2) [Mobile Application Software].  Retrieved http://itunes.apple.com.
  4. Whonamedit – dictionary of medical eponyms. http://www.whonamedit.com
  5. Addison T.  On the Constitutional and Local Effects of Disease of the Suprarenal Capsules.  1855.  London: Samuel Highley.

#19 – Parathyroid Dysfunction



LISTEN TO THE PODCAST HERE

 



Parathyroid Hormone (PTH)

Parathyroid hormone (PTH) is created and stored in the parathyroid glands and is mainly secreted in response to low serum ionized calcium levels.

picture1

PTH increases serum calcium by 3 main mechanisms:

  1. Skeletal Actions
    1. 2 phases
      1. Mobilize calcium from skeletal stores that are immediately accessible
      2. Increase osteoclastic activity
  2. Renal Actions
    1. 3 phases
      1. Increases reabsorption of calcium
        1. Mainly passively in proximal tubule
        2. Can also be actively transported in the cortical thick ascending limb of the loop of Henle and distal convoluted tubules
      2. Inhibits reabsorption of phosphate
        1. Occurs in the proximal tubule
      3. Synthesis of calcitriol
        1. Stimulates synthesis of 1-alpha hydroxylase to convert calcidiol to calcitriol
  3. Intestinal Actions
    1. Increases the intestinal absorption of calcium by calcitriol

picture1


Causes of Parathyroid Dysfunction

  • Hyperparathyroidism
    • Primary
      • Hyperfunctioning adenomas (94%)
        • Primarily parathyroid chief cells
      • Glandular hyperplasia (5%)
        • Inferior > superior
      • Carcinoma (1%)
      • Familial hypocalciuric hypercalcemia (FHH)
        • Autosomal dominant defect in calcium-sensing receptor
      • Secondary
        • Chronic renal disease, malabsorption syndromes
  • Hypoparathyroidism
    • Iatrogenic
      • Postsurgical
      • Postradiation
    • Autoimmune
      • Autoimmune polyglandular syndrome
      • Calcium-sensor receptor antibodies
    • Genetic
      • Abnormal development
      • Mutations in calcium-sensing receptor

Signs and Symptoms of Parathyroid Dysfunction

  • Hyperparathyroidism
    • “Stones”
      • Nephrolithiasis (up to 20%)
      • Renal insufficiency
    • “Bones”
      • Decreased bone mineral density
    • “Abdominal groans”
      • Nausea, vomiting, anorexia
      • Peptic ulcer disease
      • Pancreatitis
    • “Porcelain Thrones”
      • Polyuria, constipation
    • “Psychiatric moans”
      • Depression, psychosis, delirium
    • “Fatigue overtones”
      • Lethargy, fatigue
  • Hypoparathyroidism
    • Acute
      • Due to hypocalcemia postsurgery
        • Perioral numbness, paraesthesias, muscle cramps, tetany, Chvostek’s sign, Trousseau’s sign
    • Chronic
      • Basal ganglia calcifications
        • Can cause parkinsonism, dystonia, dementia
      • Cataracts
      • Dental abnormalities (congenital)
        • Dental hypoplasia, defective enamel
      • Dermal
        • Dry, puffy skin
        • Coarse, brittle, and sparse hair
        • Brittle nails

Laboratory Screening

4 main laboratory studies to help differentiate the different causes of parathyroid dysfunction:

  • Serum PTH
  • Serum calcium
  • 24-hour urinary calcium
  • Serum 25-hydroxyvitamin D

picture1

screen-shot-2016-09-26-at-6-39-00-am

picture1

Hypercalcemia Work-up


Management

  • Hypoparathyroidism
    • Acute (postsurgical)
      • 10mL ampule of 10% calcium gluconate in 50mL of D5W over 10-20 minutes followed by a calcium gluconate infusion
        • Weaned after calcium ≥ 7.5mg/dL and asymptomatic
      • Oral calcitriol (0.5 mcg BID) and calcium carbonate (0.5-2g BID)
    • Chronic
      • Oral calcium carbonate or citrate 1000-2000 mg/day
      • Oral calcitriol 0.5-2 mcg/day
      • Recombinant human PTH can be used to decrease calcium and vitamin D dosing if patients develop side effects
  • Hyperparathyroidism
    • Primary
      • Surgical Indications (any of these with laboratory findings):
        • Age < 50
        • Serum calcium ≥ 1mg/dL above upper limit of normal
        • DXA T-score ≤ -2.5
        • Vertebral fracture
        • Creatinine clearance < 60 mL/min
        • 24-hour urine calcium ≥ 400 mg/day
        • Presence of nephrolithiasis
      • Preoperative Imaging (Review of parathyroid imaging here)
        • Sestamibi-single photon emission computed tomography (MIBI-SPECT)
          • Allows for visualization of adenoma, hyperactive glands, or ectopic glands prior to surgery
          • Sensitivity – 70-81%, PPV – 91-95%
          • picture1
      • Procedure
        • Bilateral neck exploration
      • Medical
        • Bisphosphonates
          • Inhibits bone resorption and improves bone mass
          • Alendronate
        • Calcimimetics
          • Activate calcium-sensing receptors in the parathyroid gland, which decrease PTH secretion
          • Cinacalcet
        • Vitamin D
    • Secondary
      • Phosphate binders
      • Vitamin D supplementation

References

  1. Potts JT, Juppner H. Parathyroid hormone: Molecular biology and regulation. In: Principles of Bone Biology, Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego 1996. p.325.
  2. Diaz R, El-Hajj Fuleihan G, Brown EM. Regulation of parathyroid function. In: Handbook of Physiology, Section 7: The Endocrine System, Fray GGS (Ed), Oxford University Press, New York 1999.
  3. Talmage RV, Mobley HT. Calcium homeostasis: reassessment of the actions of parathyroid hormone. General and Comparative Endocrinology. 2008;156(1):1-8. [pubmed]
  4. van Abel M, Hoenderop JG, van der Kemp AW, Friedlaender MM, van Leeuwen JP, Bindels RJ. Coordinated control of renal Ca(2+) transport proteins by parathyroid hormone. Kidney International. 2005;68(4):1708-21. [pubmed]
  5. Bartsch D, Nies C, Hasse C, Willuhn J, Rothmund M. Clinical and surgical aspects of double adenoma in patients with primary hyperparathyroidism. The British Journal of Surgery. 1995;82(7):926-9. [pubmed]
  6. Ruda JM, Hollenbeak CS, Stack BC. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngology. 2005;132(3):359-72. [pubmed]
  7. Rafferty MA, Goldstein DP, Rotstein L. Completion thyroidectomy versus total thyroidectomy: is there a difference in complication rates? An analysis of 350 patients. Journal of the American College of Surgeons. 2007;205(4):602-7. [pubmed]
  8. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. The Journal of Clinical Endocrinology and Metabolism. 1996;81(6):2036-40. [pubmed]
  9. Coker LH, Rorie K, Cantley L. Primary hyperparathyroidism, cognition, and health-related quality of life. Annals of Surgery. 2005;242(5):642-50. [pubmed]
  10. Rastogi R, Beauchamp NJ, Ladenson PW. Calcification of the basal ganglia in chronic hypoparathyroidism. The Journal of Clinical Endocrinology and Metabolism. 2003;88(4):1476-7. [pubmed]
  11. Stein R, Godel V. Hypocalcemic cataract. Journal of Pediatric Ophthalmology and Strabismus. 1980;17(3):159-61. [pubmed]
  12. Kinirons MJ, Glasgow JF. The chronology of dentinal defects related to medical findings in hypoparathyroidism. Journal of Dentistry. 1985;13(4):346-9.[pubmed]
  13. Goltzman D, Cole DEC. Hypoparathyroidism. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th ed, Favus MJ. (Ed), American Society of Bone and Mineral Research, Washington, DC 2006. p.216.
  14. Winer KK, Ko CW, Reynolds JC. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. The Journal of Clinical Endocrinology and Metabolism. 2003;88(9):4214-20. [pubmed]
  15. Bilezikian JP, Brandi ML, Eastell R. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. The Journal of Clinical Endocrinology and Metabolism. 2014;99(10):3561-9. [pubmed]
  16. Eslamy HK, Ziessman HA.  Parathyroid sctinigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT.  Radiographics.  2088;28:1461-1476.

PAINE PANCE Pearl – Endocrine



What are the indications for high-intensity statin therapy for hyperlipidemia?

New joint guidelines were released in 2013 by ACC/AHA on the management of hyperlipidemia.  In these guidelines, there are 3 criteria for high intensity statin therapy:

  1. Age < 75 years with a clinical Atherosclerotic Cardiovascular Disease (ASCVD):
    1. Acute coronary syndrome
    2. Myocardial infarction
    3. Stable or unstable angina
    4. Revascularization procedures
    5. Cerebrovascular disease
    6. Peripheral arterial disease
  2. LDL ≥ 190 mg/dL
  3. Age 40-75 years, with diabetes, LDL 70-189 mg/dL, and 10-year ASCVD risk > 7.5%
screen-shot-2016-09-16-at-12-05-18-pm

2013 ACC/AHA Hyperlipidemia Guidelines


What are the drugs and dosing for high-intensity statin therapy?

There are only 2 medications that have been studied that are recommended for high-intensity statin therapy:

  1. Atorvastatin 40-80mg daily
  2. Rosuvastatin 20-40mg daily
screen-shot-2016-09-16-at-12-06-37-pm

2013 ACC/AHA Hyperlipidemia Guidelines

2013-acc-hyperlipidemia-internal-medicine2-e1411205764336

Knowmedge


Reference

  1. Stone NJ, Robinson JG, Lichtenstein AH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 63(25 Pt B):2889-934. 2014. [pubmed]